Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, provides an insight into an unanchored, matching-adjusted indirect comparison (MAIC) comparing the efficacy of epcoritamab to the standard of care (SoC) in patients with relapsed/refractory (R/R) follicular lymphoma (FL). The data for the SoC group came from the SCHOLAR-5 real-world cohort, and the data for the epcoritamab group came from the pivotal EPCORE NHL-1 trial (NCT03625037). The findings of this analysis suggest that treatment with epcoritamab results in a higher overall response rate (ORR) and confers a survival benefit. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Негізгі бет Epcoritamab vs SoC (SCHOLAR-5 cohort) in patients with R/R FL
Пікірлер